Table 2.
Baseline characteristics
|
Treatment sequences | |||
|---|---|---|---|
|
Characteristic |
Rhodiola
– placebo |
Placebo –
Rhodiola
|
P
value |
| (N = 48) | (N = 54) | ||
| Male |
23 (47.9) |
27 (50.0) |
0.83 |
| Age, y |
35.8 ± 10.0 |
36.3 ± 10.4 |
0.84 |
| BMI, kg/m2 |
22.6 ± 2.9 |
23.4 ± 3.0 |
0.17 |
| SpO2*, % |
98.8 ± 0.9 |
98.9 ± 1.0 |
0.60 |
| Heart rate, beats/min |
72.5 ± 8.9 |
72.2 ± 9.6 |
0.89 |
| Altitude of residence, m |
151.7 ± 105.9 |
152.7 ± 105.9 |
0.94 |
| History of mountaineering above 3000 m |
|
|
0.18 |
| Never |
23 (47.9) |
36 (66.7) |
|
| <10 mountains |
20 (41.7) |
16 (29.6) |
|
| >10 mountains |
5 (10.4) |
2 (3.7) |
|
| History of AMS | 7 (14.6) | 5 (9.3) | 0.54 |
Continuous variables are presented as mean ± standard deviation, and categorical variables are presented as count (percentage).
BMI, Body mass index.
*SpO2, Oxygen saturation by pulse oximetry at an altitude of 250 m. Heart rate and other demographics were measured during the participant conference before randomization.
AMS, Acute mountain sickness.